Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

7.810 -0.240 (-2.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday
The biotech's board is exploring strategic alternatives to boost shareholder value. 
Via The Motley Fool
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top... 
Via Benzinga
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout
The company makes a lupus nephritis treatment that could easily bolt onto a suitor, analysts say. 
Via Investor's Business Daily
Why Are Aurinia Pharmaceuticals Shares Trading Higher Today
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) initiated an exploration of strategic alternatives, including a potential sale, merger, or  
Via Benzinga
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. 
Via Benzinga
Aurinia Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Aurinia Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Why Aurinia Pharmaceuticals Stock Is Glowing Green Today
Investors appear to be cheering another patent win by the company. 
Via The Motley Fool
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today! 
Via InvestorPlace
Tesla, Nike, Sigilon Therapeutics Among Top Trending Stocks Today
Via Benzinga
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
From Aurinia Pharmaceuticals Inc.
Via Business Wire
LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces 2023 Annual General Meeting Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tesla, AMD, Ford, Starbucks, Aurinia Pharma: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting
From Aurinia
Via Business Wire
3 Biotechs That Might Get Bought Out in 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Second Quarter Outlook For Biotech Stocks
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday
Via Benzinga
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS